Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian StudyVirginia Solitano, Vipul Jairath, Talat Bessissow et al.|The American Journal of Gastroenterology|2025Cited by 10
P0860 Long-term outcomes of extended versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission: 3-year follow-up of the randomized controlled LADI trialMartine Devillers, Frank Hoentjen, L van Lierop et al.|Journal of Crohn s and Colitis|2025Cited by 0